We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Affirm
AFRM
$25.3B
| $11.3M | 0.25% |
+159,568
| New | +$15.5M |
|
|
DISH
102
DELISTED
DISH Network Corp.
DISH
| $11.2M | 0.25% |
309,484
+93,481
| +43% | +$3.11M |
|
|
TRIL
103
DELISTED
Trillium Therapeutics Inc.
TRIL
| $11.1M | 0.25% |
1,034,991
+273,526
| +36% | +$3.38M |
|
|
JNPR
104
DELISTED
Juniper Networks
JNPR
| $11.1M | 0.25% |
+437,327
| New | +$10.8M |
|
105
Knowles
KN
$3.2B
| $10.9M | 0.24% |
522,165
-200,814
| -28% | -$4.09M |
|
106
Corcept Therapeutics
CORT
$12.2B
| $10.9M | 0.24% |
458,501
-107,391
| -19% | -$2.87M |
|
|
NAPA
107
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $10.9M | 0.24% |
+647,735
| New | +$11.7M |
|
108
Ericsson
ERIC
$33.1B
| $10.8M | 0.24% |
818,237
-71,037
| -8% | -$904K |
|
109
Airbnb
ABNB
$89.4B
| $10.8M | 0.24% |
57,309
+7,309
| +15% | +$1.35M |
|
|
IPG
110
DELISTED
Interpublic Group of Companies
IPG
| $10.8M | 0.24% |
368,801
+293,807
| +392% | +$7.75M |
|
111
Seer Inc
SEER
$123M
| $10.7M | 0.24% |
213,151
-12,381
| -5% | -$724K |
|
112
Zai Lab
ZLAB
$2.05B
| $10.5M | 0.23% |
78,902
+17,532
| +29% | +$2.71M |
|
|
HMCO
113
DELISTED
HumanCo Acquisition Corp. Class A Common Stock
HMCO
| $10.5M | 0.23% |
+1,055,321
| New | +$11M |
|
114
Fate Therapeutics
FATE
$291M
| $10.4M | 0.23% |
+126,360
| New | +$12.1M |
|
|
ABMD
115
DELISTED
Abiomed Inc
ABMD
| $10.2M | 0.23% |
+31,907
| New | +$10.2M |
|
116
Acadia Pharmaceuticals
ACAD
$4.39B
| $10.1M | 0.22% |
390,591
+339,678
| +667% | +$15M |
|
117
Baidu
BIDU
$38.3B
| $10.1M | 0.22% |
+46,239
| New | +$12.1M |
|
|
ITCI
118
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.98M | 0.22% |
294,285
-30,482
| -9% | -$1.06M |
|
119
Simply Good Foods
SMPL
$1B
| $9.94M | 0.22% |
326,820
-21,290
| -6% | -$634K |
|
120
McKesson
MCK
$96.8B
| $9.89M | 0.22% |
+50,708
| New | +$9.26M |
|
121
TD Synnex
SNX
$20.3B
| $9.75M | 0.22% |
+84,921
| New | +$7.93M |
|
122
Chewy
CHWY
$9.4B
| $9.55M | 0.21% |
112,704
+25,861
| +30% | +$2.52M |
|
123
Eledon Pharmaceuticals
ELDN
$265M
| $9.53M | 0.21% |
891,055
-1,500
| -0.2% | -$22.6K |
|
124
AnaptysBio
ANAB
$1.59B
| $9.24M | 0.21% |
+428,847
| New | +$10.8M |
|
125
Charles River Laboratories
CRL
$11.1B
| $9.2M | 0.2% |
31,736
+5,533
| +21% | +$1.54M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.